Active Comparator Biological/Vaccine,Active Comparator Biological/Vaccine,Active Comparator Biological/Vaccine,Active Comparator Biological/Vaccine,Active Comparator Biological/Vaccine,Active Comparat

4 trials

Sponsors

Chulabhorn Royal Academy, Faculty of Medicine Siriraj Hospital, Mahidol University, National Research Council of Thailand (NRCT)

Conditions

After the third dose of the COVID-19 vaccine, the immune response in healthy volunteers who received 2 doses of COVID19 vaccine (CoronaVac or ChAdOx1) at least three months. COVID-19 vaccine, Third dose, ChAdOx1, coronavac, Sinovac, BNT162b2, SinopharmHealthy Thai individuals aged 18 years and above immunogenicity, COVID-19. vaccine, boosterThe immune response after the third dose of the COVID-19 vaccine via intradermal administration in healthy volunteers. COVID-19 vaccine, Third dose, intradermal, ChAdOx1, coronavac, Sinovac, BNT162b2, mRNA1263, Sinopharmhealthy volunteer Safety and Immunological Response Intradermal COVID-19 vaccination

Phase 1

A Pilot Study: Safety and Immunological Response following Intradermal COVID-19 vaccination in The Booster (3rd dose)

Active, not recruitingTCTR20210907003

Faculty of Medicine Siriraj Hospital, Mahidol Universityhealthy volunteer Safety and Immunological Response Intradermal COVID-19 vaccination

Start: 2021-09-11Target: 60Updated: 2026-08-03

Phase 2

Immunogenicity and safety of the third dose COVID-19 vaccine via intradermal compare with intramuscular administration (Randomized controlled trial)

RecruitingTCTR20210731003

Chulabhorn Royal AcademyThe immune response after the third dose of the COVID-19 vaccine via intradermal administration in healthy volunteers. COVID-19 vaccine, Third dose, intradermal, ChAdOx1, coronavac, Sinovac, BNT162b2, mRNA1263, Sinopharm

Start: 2021-08-09Target: 960Updated: 2026-08-03

Immunogenicity and safety of the third dose COVID-19 vaccine in Thai population.

RecruitingTCTR20210731004

Chulabhorn Royal AcademyAfter the third dose of the COVID-19 vaccine, the immune response in healthy volunteers who received 2 doses of COVID19 vaccine (CoronaVac or ChAdOx1) at least three months. COVID-19 vaccine, Third dose, ChAdOx1, coronavac, Sinovac, BNT162b2, Sinopharm

Start: 2021-08-05Target: 5520Updated: 2026-08-03

Phase 4

Immunogenicity of the third COVID-19 vaccine booster dose in adults with completed 2 doses as recommended by the ministry of public health

Active, not recruitingTCTR20211120002

National Research Council of Thailand (NRCT)Healthy Thai individuals aged 18 years and above immunogenicity, COVID-19. vaccine, booster

Start: 2021-11-05Target: 300Updated: 2026-08-03